Neuigkeiten

Neuigkeiten aus dem GMP-Umfeld und von der Valicare GmbH

Nachrichten aus aller Welt

Unser internationaler Pressespiegel zeigt eine Auswahl an Nachrichten und neusten Artikel zu den Themen Arzneimittel neuartiger Therapien (ATMP), Chimäre Antigenrezeptor(CAR)-T-Zell-Therapie, Tumor infiltrierende Lymphozyten (TIL) und biotechnologisch bearbeitete Gewebeprodukte (TEP).

Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study

02.04.2021 | World Pharma News

April 2: The Week in Cancer News

02.04.2021 | Cancer Today

A study indicates that people are delaying medical care until they are eligible for Medicare, leading to missed cancers, and the Food and ...

PharmaShots Weekly Snapshots (Mar 29 – Apr 02, 2021)

02.04.2021 | PharmaShots

Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19

Choosing the Right Viral Vector for a Gene Therapy - Global Genes

02.04.2021 | Global Genes

Gene therapy is promising to provide treatments and potential cures for a long list of rare, genetic diseases. A key element of these ...

Stem cell transplants prevent relapses of most common childhood cancer

02.04.2021 | Science Codex

Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer ...

Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment

02.04.2021 | Frontiers

The tumor immune microenvironment (TIME), an immunosuppressive niche, plays a pivotal role in contributing to the development, progression ...

The evolution of commercial drug delivery technologies

01.04.2021 | Nature

This Review Article discusses how delivery challenges associated with small molecules, nucleic acids, peptides, proteins and cells led to ...

IQWiG soll Konzept für anwendungsbegleitende Datenerhebung...

01.04.2021 | Arzteblatt.de

Celltrion Healthcare receives positive CHMP opinion for subcutaneous formulation of infliximab, Remsima® SC, for direct use of subcutaneous therapy without IV loading in adults with rheumatoid arthritis

31.03.2021 | Le Lezard (EN)

A T-cell independent universal cellular therapy strategy through antigen depletion

30.03.2021 | bioRxiv

CD19-targeting chimeric antigen receptor (CAR) T-cell therapeutics is a revolutionary, novel and successful treatment for B-cell ...

Celonic will manufacture over 100 million doses of Curevac’s COVID-19 Vaccine Candid...

30.03.2021 | BioPharmAnalyses

CureVac and Celonic Group have conclud a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV. ...

Systematic analysis of CD39, CD103, CD137 and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs

30.03.2021 | bioRxiv

The detection of tumor-specific T cells in solid tumors is integral to the interrogation of endogenous antitumor responses and to the ...

FDA Approves Bristol Myers Squibb and bluebird bio’s CAR T Cell Therapy for Refractory Multiple Myeloma

29.03.2021 | BioPharm International

Abecma is the first B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy for the treatment of adult patients ...

Bristol Myers Squibb Expands Devens Facility for Cancer Research

29.03.2021 | The New England Council

NEC member Bristol Myers Squibb, a New York-based biopharmaceutical company, recently added a 244,000 square-foot expansion to their Devens ...

Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I

29.03.2021 | Le Lezard (EN)

Wir sind für Sie da

Kontaktieren Sie uns, wenn Sie Fragen haben. Wir antworten und beraten Sie gerne. 

Kontakt